ArticleScientific reports2026
CQMUH-011 mitigated LPS-induced acute lung injury in neonatal rabbits.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Neonatal sepsis-associated acute lung injury (ALI) remains a major clinical challenge. This study investigated the protective effects of a novel small-molecule compound, CQMUH-011, in a neonatal rabbit model of hyper-acute endotoxin shock with secondary ALI. Neonatal rabbits were intraperitoneally injected with lipopolysaccharide (50 mg/kg), followed by CQMUH-011 (75, 225, 675 µg/kg) or dexamethasone (Dex, 1.5 mg/kg) at 0.5 h. Over a 10-hour observation period, despite a non-significant trend in overall survival, CQMUH-011 dose-dependently mitigated neurological deficits, restored blood gas balance, enriched the phospholipid pool, reduced inflammatory lung injury and improved alveolar expansion. At the mRNA level, CQMUH-011 suppressed proinflammatory cytokines and upregulated surfactant-associated enzymes. The lung-protective effects of CQMUH-011 were comparable to those of Dex, or better on selected endpoints. Exploratory transcriptomic profiling suggested CQMUH-011 may function by downregulating multiple inflammatory pathways concurrent with the potential modulation of phosphatidylinositol 3-kinase/protein kinase B-dependent cytoprotection, cytoskeletal remodeling, and intercellular junction reinforcement. However, these transcriptomic signatures currently lack confirmatory protein-level testing. In conclusion, CQMUH-011 demonstrates preliminary lung-protective effects in this acute neonatal endotoxin shock paradigm. Rather than a definitive therapeutic candidate, CQMUH-011 represents an early-stage proof-of-concept molecule requiring extensive future pharmacokinetic characterization and mechanistic validation to establish its translational potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.